Atlas Trials

Retrospective Assessment of AE-Related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma

Clinical trial NCT05874817 · COMPLETED

Trial details

NCT number
NCT05874817
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Study type
OBSERVATIONAL
Melanoma
Start date
2021-05-01
Primary completion
2022-05-20
Enrollment
17517

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.